GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Feedback PLC (LSE:FDBK) » Definitions » Net Income Including Noncontrolling Interests

Feedback (LSE:FDBK) Net Income Including Noncontrolling Interests : £-3.49 Mil (TTM As of Nov. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Feedback Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Feedback's Net Income Including Noncontrolling Interests for the six months ended in Nov. 2023 was £-1.94 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Nov. 2023 was £-3.49 Mil.

Feedback Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Feedback's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feedback Net Income Including Noncontrolling Interests Chart

Feedback Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.97 -1.09 -1.62 -2.12 -2.92

Feedback Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 -1.06 -1.37 -1.55 -1.94

Feedback Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Nov. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-3.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feedback Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Feedback's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Feedback (LSE:FDBK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Feedback PLC (LSE:FDBK) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
LSE:INHC LSE:IQAI LSE:TRLS LSE:COG AQSE:DXSP LSE:RENX GEHC VEEV SOLV ASX:PME HQY TSE:2413 RCM DOCS TXG CERT GDRX EVH PGNY PRVA
Traded in Other Exchanges
N/A
Address
3-7 Temple Avenue, 201 Temple Chambers, London, GBR, EC4Y 0DT
Website
https://www.fbkmed.com
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. The company also entered into a joint venture for future clinical application of its products on patients with kidney stones and it has a medical imaging segment.

Feedback (LSE:FDBK) Headlines

No Headlines